Loading...
XASXAVR
Market cap200mUSD
Dec 27, Last price  
8.85AUD
1D
0.00%
1Q
-29.14%
Jan 2017
-75.42%
Name

Anteris Technologies Ltd

Chart & Performance

D1W1MN
XASX:AVR chart
P/E
—
P/S
77.37
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
2.46%
Rev. gr., 5y
-30.64%
Revenues
4m
-10.43%
0000006,749,7166,435,6537,402,9887,900,09510,133,46014,150,52122,324,14522,610,15825,601,09717,075,3837,078,7837,790,9574,590,0474,111,081
Net income
-67m
L+51.86%
-1,767,760-1,111,468-2,089,187-1,126,607-1,020,112-1,174,312-1,420,596-9,995,227-1,892,406-6,616,498-25,253,843-24,013,868-12,312,076-17,263,572-24,217,169-5,819,673-15,274,534-22,907,027-44,340,161-67,333,386
CFO
-51m
L+31.89%
-720,484-534,480-1,505,904-921,637-994,446-1,239,557-1,470,916-3,535,754-3,697,260-10,644,351-21,496,204-21,940,524-12,467,781-13,252,614-22,205,313-22,867,298-14,373,162-18,809,609-38,995,191-51,432,580
Earnings
Feb 26, 2025

Profile

Anteris Technologies Ltd operates as a structural heart company. It manufactures and sells ADAPT, a regenerative tissue product. The company also engages in the developing of DurAVRTM, a 3D single piece aortic valve for the treatment of aortic stenosis. In addition, it researches and develops regenerative medicines. The company was formerly known as Admedus Limited and changed its name to Anteris Technologies Ltd in May 2020. Anteris Technologies Ltd was incorporated in 1999 and is based in Toowong, Australia.
URL
https://anteristech.com/
IPO date
Mar 24, 2004
Employees
Domiciled in
AU
Incorporated in
AU

Valuation

Title
AUD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122017‑062016‑062015‑06
Income
Revenues
4,111
-10.43%
4,590
-41.08%
7,791
10.06%
Cost of revenue
61,069
48,044
28,283
Unusual Expense (Income)
NOPBT
(56,957)
(43,454)
(20,492)
NOPBT Margin
Operating Taxes
(187)
(1,404)
(1,374)
Tax Rate
NOPAT
(56,770)
(42,051)
(19,118)
Net income
(67,333)
51.86%
(44,340)
93.57%
(22,907)
49.97%
Dividends
Dividend yield
Proceeds from repurchase of equity
78,932
31,959
34,666
BB yield
-26.41%
-10.42%
-19.36%
Debt
Debt current
978
757
5,308
Long-term debt
3,688
1,298
843
Deferred revenue
Other long-term liabilities
1,859
2,072
1,771
Net debt
(26,166)
(11,750)
(15,149)
Cash flow
Cash from operating activities
(51,433)
(38,995)
(18,810)
CAPEX
(3,552)
(2,409)
(773)
Cash from investing activities
(3,902)
(1,360)
(1,162)
Cash from financing activities
72,950
31,364
36,908
FCF
(60,080)
(44,071)
(19,184)
Balance
Cash
30,832
13,805
21,300
Long term investments
Excess cash
30,626
13,576
20,910
Stockholders' equity
28,662
13,218
14,348
Invested Capital
4,192
3,478
7,500
ROIC
ROCE
EV
Common stock shares outstanding
15,606
13,818
13,818
Price
19.15
-13.74%
22.20
71.30%
12.96
 
Market cap
298,853
-2.57%
306,750
71.30%
179,076
 
EV
272,747
295,000
163,927
EBITDA
(54,167)
(41,712)
(19,138)
EV/EBITDA
Interest
430
967
1,504
Interest/NOPBT